Injection-site reactions are the most common treatment-related adverse drug reactions. Other common adverse drug reactions reported are headache (15%), arthralgia (15%), pyrexia (6%), and diarrhea (6%).

Similar to FVIII replacement therapy, emicizumab has the potential for immunogenicity. Per the emicizumab prescribing information, 3.5% of patients in the HAVEN clinical trials tested positive for anti-emicizumab antibodies, though less than 1% developed antibodies with neutralizing potential.